DK2456889T3 - Markører for endometriel cancer - Google Patents
Markører for endometriel cancer Download PDFInfo
- Publication number
- DK2456889T3 DK2456889T3 DK10736990.2T DK10736990T DK2456889T3 DK 2456889 T3 DK2456889 T3 DK 2456889T3 DK 10736990 T DK10736990 T DK 10736990T DK 2456889 T3 DK2456889 T3 DK 2456889T3
- Authority
- DK
- Denmark
- Prior art keywords
- cáncer
- endometrial
- biomarkers
- p4hb
- level
- Prior art date
Links
- 206010014759 Endometrial neoplasm Diseases 0.000 title claims description 26
- 206010014733 Endometrial cancer Diseases 0.000 title claims description 20
- 230000002357 endometrial effect Effects 0.000 claims description 682
- 239000000090 biomarker Substances 0.000 claims description 619
- 239000000523 sample Substances 0.000 claims description 420
- 101001072202 Homo sapiens Protein disulfide-isomerase Proteins 0.000 claims description 305
- 102100036352 Protein disulfide-isomerase Human genes 0.000 claims description 305
- 229920002791 poly-4-hydroxybutyrate Polymers 0.000 claims description 305
- 101710102635 GEM-interacting protein Proteins 0.000 claims description 235
- 102100034265 GEM-interacting protein Human genes 0.000 claims description 235
- 102100021857 Inhibitor of nuclear factor kappa-B kinase subunit epsilon Human genes 0.000 claims description 230
- 239000012530 fluid Substances 0.000 claims description 210
- 230000001965 increasing effect Effects 0.000 claims description 178
- 101000687808 Homo sapiens Suppressor of cytokine signaling 2 Proteins 0.000 claims description 166
- 102100024784 Suppressor of cytokine signaling 2 Human genes 0.000 claims description 166
- 102100028067 EGF-containing fibulin-like extracellular matrix protein 2 Human genes 0.000 claims description 161
- 101001060248 Homo sapiens EGF-containing fibulin-like extracellular matrix protein 2 Proteins 0.000 claims description 161
- 101000616738 Homo sapiens NAD-dependent protein deacetylase sirtuin-6 Proteins 0.000 claims description 142
- 102100021840 NAD-dependent protein deacetylase sirtuin-6 Human genes 0.000 claims description 142
- 102100037789 FAST kinase domain-containing protein 1, mitochondrial Human genes 0.000 claims description 134
- 101000878541 Homo sapiens FAST kinase domain-containing protein 1, mitochondrial Proteins 0.000 claims description 134
- 101710131668 Epithelial discoidin domain-containing receptor 1 Proteins 0.000 claims description 132
- 102100036725 Epithelial discoidin domain-containing receptor 1 Human genes 0.000 claims description 132
- 101000731078 Homo sapiens Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Proteins 0.000 claims description 131
- 102100032391 Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Human genes 0.000 claims description 131
- 238000000034 method Methods 0.000 claims description 129
- 230000014509 gene expression Effects 0.000 claims description 123
- 102100035218 Epidermal growth factor receptor kinase substrate 8-like protein 2 Human genes 0.000 claims description 116
- 101000876686 Homo sapiens Epidermal growth factor receptor kinase substrate 8-like protein 2 Proteins 0.000 claims description 116
- 101001098179 Homo sapiens P2X purinoceptor 4 Proteins 0.000 claims description 106
- 102100037601 P2X purinoceptor 4 Human genes 0.000 claims description 106
- 108090000623 proteins and genes Proteins 0.000 claims description 104
- 102100040322 E3 ubiquitin-protein ligase RNF183 Human genes 0.000 claims description 98
- 101001104297 Homo sapiens E3 ubiquitin-protein ligase RNF183 Proteins 0.000 claims description 98
- 101001122747 Homo sapiens Protein phosphatase 1 regulatory subunit 16A Proteins 0.000 claims description 97
- 102100028722 Protein phosphatase 1 regulatory subunit 16A Human genes 0.000 claims description 97
- 101000712974 Homo sapiens Ras association domain-containing protein 7 Proteins 0.000 claims description 96
- 101000785517 Homo sapiens Tight junction protein ZO-3 Proteins 0.000 claims description 96
- 102100033241 Ras association domain-containing protein 7 Human genes 0.000 claims description 96
- 102100026640 Tight junction protein ZO-3 Human genes 0.000 claims description 96
- 102100039217 3-ketoacyl-CoA thiolase, peroxisomal Human genes 0.000 claims description 93
- 101000670146 Homo sapiens 3-ketoacyl-CoA thiolase, peroxisomal Proteins 0.000 claims description 92
- 102100034531 AP-1 complex subunit mu-2 Human genes 0.000 claims description 89
- 102100033473 Cingulin Human genes 0.000 claims description 89
- 101000924636 Homo sapiens AP-1 complex subunit mu-2 Proteins 0.000 claims description 89
- 101001064427 Homo sapiens Liprin-beta-2 Proteins 0.000 claims description 88
- 102100031981 Liprin-beta-2 Human genes 0.000 claims description 88
- 102100035784 Decorin Human genes 0.000 claims description 85
- 101001000206 Homo sapiens Decorin Proteins 0.000 claims description 85
- 108020004999 messenger RNA Proteins 0.000 claims description 83
- 238000000338 in vitro Methods 0.000 claims description 64
- 238000002405 diagnostic procedure Methods 0.000 claims description 53
- 238000003748 differential diagnosis Methods 0.000 claims description 47
- 238000003745 diagnosis Methods 0.000 claims description 42
- 238000003757 reverse transcription PCR Methods 0.000 claims description 38
- 210000002966 serum Anatomy 0.000 claims description 34
- 210000004369 blood Anatomy 0.000 claims description 33
- 239000008280 blood Substances 0.000 claims description 33
- 230000000295 complement effect Effects 0.000 claims description 30
- 239000002299 complementary DNA Substances 0.000 claims description 29
- 239000000092 prognostic biomarker Substances 0.000 claims description 23
- 150000007523 nucleic acids Chemical class 0.000 claims description 20
- 102000039446 nucleic acids Human genes 0.000 claims description 19
- 108020004707 nucleic acids Proteins 0.000 claims description 19
- -1 SIRT63 Proteins 0.000 claims description 18
- 238000001514 detection method Methods 0.000 claims description 15
- 210000004696 endometrium Anatomy 0.000 claims description 15
- 208000024891 symptom Diseases 0.000 claims description 15
- 238000003753 real-time PCR Methods 0.000 claims description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 9
- 238000012216 screening Methods 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 208000037853 Abnormal uterine bleeding Diseases 0.000 claims description 5
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims description 5
- 102100021429 DNA-directed RNA polymerase II subunit RPB1 Human genes 0.000 claims description 5
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims description 5
- 101001106401 Homo sapiens DNA-directed RNA polymerase II subunit RPB1 Proteins 0.000 claims description 5
- 101000577619 Homo sapiens Profilin-1 Proteins 0.000 claims description 5
- 102100028857 Profilin-1 Human genes 0.000 claims description 5
- 230000015556 catabolic process Effects 0.000 claims description 5
- 238000006731 degradation reaction Methods 0.000 claims description 5
- 101000944124 Homo sapiens Cingulin Proteins 0.000 claims 7
- 101100508538 Homo sapiens IKBKE gene Proteins 0.000 claims 7
- 108050002485 Sirtuin Proteins 0.000 claims 1
- 102000011990 Sirtuin Human genes 0.000 claims 1
- 239000013610 patient sample Substances 0.000 claims 1
- 101710164304 Inhibitor of nuclear factor kappa-B kinase subunit epsilon Proteins 0.000 description 222
- 206010028980 Neoplasm Diseases 0.000 description 100
- 101710122611 Cingulin Proteins 0.000 description 82
- 210000001519 tissue Anatomy 0.000 description 77
- 230000000875 corresponding effect Effects 0.000 description 74
- 102000004169 proteins and genes Human genes 0.000 description 70
- 235000018102 proteins Nutrition 0.000 description 51
- 230000002596 correlated effect Effects 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 24
- 230000035945 sensitivity Effects 0.000 description 21
- 230000003248 secreting effect Effects 0.000 description 11
- 238000002493 microarray Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000004393 prognosis Methods 0.000 description 9
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 239000013641 positive control Substances 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 201000006828 endometrial hyperplasia Diseases 0.000 description 6
- 208000023965 endometrium neoplasm Diseases 0.000 description 6
- 229940011871 estrogen Drugs 0.000 description 6
- 239000000262 estrogen Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 206010003504 Aspiration Diseases 0.000 description 5
- 102100028843 DNA mismatch repair protein Mlh1 Human genes 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 101710191461 F420-dependent glucose-6-phosphate dehydrogenase Proteins 0.000 description 4
- 102100035172 Glucose-6-phosphate 1-dehydrogenase Human genes 0.000 description 4
- 101710155861 Glucose-6-phosphate 1-dehydrogenase Proteins 0.000 description 4
- 101710174622 Glucose-6-phosphate 1-dehydrogenase, chloroplastic Proteins 0.000 description 4
- 101710137456 Glucose-6-phosphate 1-dehydrogenase, cytoplasmic isoform Proteins 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 101000577853 Homo sapiens DNA mismatch repair protein Mlh1 Proteins 0.000 description 4
- 102100034391 Porphobilinogen deaminase Human genes 0.000 description 4
- 101710189720 Porphobilinogen deaminase Proteins 0.000 description 4
- 101710170827 Porphobilinogen deaminase, chloroplastic Proteins 0.000 description 4
- 101710100896 Probable porphobilinogen deaminase Proteins 0.000 description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 description 4
- 206010046788 Uterine haemorrhage Diseases 0.000 description 4
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 4
- 208000034158 bleeding Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 208000016018 endometrial polyp Diseases 0.000 description 4
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 4
- 229960001603 tamoxifen Drugs 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 206010046811 uterine polyp Diseases 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 101000609211 Homo sapiens Polyadenylate-binding protein 2 Proteins 0.000 description 3
- 102100039427 Polyadenylate-binding protein 2 Human genes 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 201000003914 endometrial carcinoma Diseases 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000027758 ovulation cycle Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 206010046901 vaginal discharge Diseases 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 206010000084 Abdominal pain lower Diseases 0.000 description 2
- 235000019737 Animal fat Nutrition 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 208000033206 Early menarche Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102100030708 GTPase KRas Human genes 0.000 description 2
- 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 description 2
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100034256 Mucin-1 Human genes 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000006994 Precancerous Conditions Diseases 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000003756 cervix mucus Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 201000003908 endometrial adenocarcinoma Diseases 0.000 description 2
- 208000029382 endometrium adenocarcinoma Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 230000003821 menstrual periods Effects 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000002974 pharmacogenomic effect Effects 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 229940070376 protein Drugs 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- IDGZVZJLYFTXSL-UHFFFAOYSA-N 2-[[2-[(2-amino-4-methylpentanoyl)amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CC(C)CC(N)C(=O)NC(CO)C(=O)NC(C(O)=O)CCCN=C(N)N IDGZVZJLYFTXSL-UHFFFAOYSA-N 0.000 description 1
- 101150100859 45 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102100028914 Catenin beta-1 Human genes 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 102000004214 DNA polymerase A Human genes 0.000 description 1
- 108090000725 DNA polymerase A Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 102100034237 Endosome/lysosome-associated apoptosis and autophagy regulator 1 Human genes 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 208000006334 Gingival Fibromatosis Diseases 0.000 description 1
- 101150054472 HER2 gene Proteins 0.000 description 1
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 description 1
- 208000030839 Hereditary gingival fibromatosis Diseases 0.000 description 1
- 206010051922 Hereditary non-polyposis colorectal cancer syndrome Diseases 0.000 description 1
- 101100153048 Homo sapiens ACAA1 gene Proteins 0.000 description 1
- 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 description 1
- 101000925880 Homo sapiens Endosome/lysosome-associated apoptosis and autophagy regulator 1 Proteins 0.000 description 1
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
- 101001065663 Homo sapiens Lipolysis-stimulated lipoprotein receptor Proteins 0.000 description 1
- 102100032010 Lipolysis-stimulated lipoprotein receptor Human genes 0.000 description 1
- 201000005027 Lynch syndrome Diseases 0.000 description 1
- 108010063312 Metalloproteins Proteins 0.000 description 1
- 102000010750 Metalloproteins Human genes 0.000 description 1
- 108010026664 MutL Protein Homolog 1 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 206010055870 Postmenopausal haemorrhage Diseases 0.000 description 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
- 102000004265 STAT2 Transcription Factor Human genes 0.000 description 1
- 108010081691 STAT2 Transcription Factor Proteins 0.000 description 1
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 208000016599 Uterine disease Diseases 0.000 description 1
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000011099 endometrial disease Diseases 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 108700020302 erbB-2 Genes Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000006894 menstrual cycle phase Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000033607 mismatch repair Effects 0.000 description 1
- 230000002632 myometrial effect Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000013515 script Methods 0.000 description 1
- 238000003375 selectivity assay Methods 0.000 description 1
- 208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 231100000622 toxicogenomics Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 238000003160 two-hybrid assay Methods 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57442—Specifically defined cancers of the uterus and endometrial
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Claims (29)
1. ln vitro diagnostisk fremgangsmáde til diagnose af endometriel cáncer, hvilken frem-gangsmáde omfatter detektion af niveauet af biomarkoren P4HB i en preve fra en pati-ent, hvor et foreget niveau af P4HB i sammenligning med en kontrolvaerdi indikerer forekomst af endometriel cáncer.
2. In vitro diagnostisk fremgangsmáde ifelge krav 1, som desuden omfatter detektion af niveauet af GMIP, IKBKE eller EFEMP2.
3. In vitro diagnostisk fremgangsmáde ifelge krav 1, som desuden omfatter detektion af niveauet af FASTKD1.
4. In vitro diagnostisk fremgangsmáde ifolge krav 1, som desuden omfatter detektion af niveauet af DDR1.
5. In vitro diagnostisk fremgangsmáde ifolge krav 1, som desuden omfatter detektion af niveauet af SIRT6.
6. In vitro diagnostisk fremgangsmáde ifolge krav 1, som desuden omfatter detektion af niveauet af PHKG2.
7. In vitro diagnostisk fremgangsmáde ifolge krav 1, som desuden omfatter detektion af niveauet af en biomarkor, der er valgt blandt ACAA1, AP1M2, EPS8L2, P2RX4, PPFIBP2, PPP1R16A, CGN, RASSF7, RNF183, TJP3, SOCS2 og DCN.
8. In vitro diagnostisk fremgangsmáde ifolge et hvilket som helst af kravene 1 til 7, hvor patienten har en risikofaktor for endometriel cáncer eller er under screening for endometriel cáncer.
9. In vitro diagnostisk fremgangsmáde ifolge et hvilket som helst af kravene 1 til 8, hvor proven fra patienten erfra en patient med abnorm uterin blodning.
10. In vitro diagnostisk fremgangsmáde ifolge et hvilket som helst af kravene 1 til 9, hvor proven fra patienten erfra en patient, som har et endometrium med foroget tyk-kelse.
11. In vitro diagnostisk fremgangsmáde ifolge et hvilket som helst af kravene 1 til 10, hvor proven fra patienten erfra en prae-menopausal, peri-menopausal eller post-meno-pausal patient.
12. In vitro diagnostisk fremgangsmáde ifolge krav 11, hvor patienten er post-meno-pausal.
13. In vitro diagnostisk fremgangsmáde ifolge et hvilket som helst af kravene 1 til 12, hvor proven er valgt blandt en vaevsprove, blod og/eller serum og uterin vaeske.
14. In vitro diagnostisk fremgangsmáde ifolge krav 13, hvor proven er en uterin vae-skeprove.
15. In vitro diagnostisk fremgangsmáde ifolge krav 14, hvor den uterine vaeskeprove er opnáet ved aspiration.
16. In vitro diagnostisk fremgangsmáde ifolge et hvilket som helst af kravene 1 til 15, hvor niveauet af biomarkoren P4HB og eventuelt én biomarkor, der er valgt blandt GMIP, IKBKE, FASTKD1, DDR1, SIRT6, PHKG2, ACAA1, AP1M2, EPS8L2, P2RX4, PPFIBP2, PPP1R16A, CGN, RASSF7, RNF183, TJP3, EFEMP2, SOCS2 og DCN, bestemmes med et antistof.
17. In vitro diagnostisk fremgangsmáde ifolge et hvilket som helst af kravene 1 til 15, hvor niveauet af biomarkoren P4HB og eventuelt én biomarkor, der er valgt blandt GMIP, IKBKE, FASTKD1, DDR1,SIRT6, PHKG2, ACAA1, AP1M2, EPS8L2, P2RX4, PPFIBP2, PPP1R16A, CGN, RASSF7, RNF183, TJP3, EFEMP2, SOCS2 og DCN, bestemmes ved RT-PCR.
18. In vitro diagnostisk fremgangsmáde ifolge et hvilket som helst af kravene 2 til 17, hvor der detekteres fra 2 til 20 markorer.
19. In vitro diagnostisk fremgangsmáde ifolge et hvilket som helst af kravene 1 til 18, hvor der detekteres én eller flere yderligere biomarkorer.
20. In vitro diagnostisk fremgangsmáde ifolge krav 19, hvor den ene eller de flere yderligere biomarkorer er valgt blandt differential diagnose-biomarkorer, prognostiske biomarkorer, biomarkorer, som er nyttige til detektion af endometriel cáncer, biomarkorer til klassificering af endometriel cáncer og hjaelpebiomarkorer til detektion af endometriel cáncer.
21. In vitro diagnostisk fremgangsmáde ifolge et hvilket som helst af kravene 1 til 15 og 17 til 20, hvilken fremgangsmáde omfatter, at der tilvejebringes en uterin vaeskeprove, som er opnáet fra en patient med en pipelleindretning eller sprojte, hvor patienten har en risikofaktor for eller et symptom pá endometriel cáncer; proven bringes i kontakt med et middel, som er i stand til at konservere, forebygge eller formindske nedbrydningen af RNA i den uterine vaeskeprove; i proven bestemmes ekspressionsniveauet af mRNA svarende til biomarkoren P4HB og eventuelt én biomarkor, der er valgt blandt ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, PHKG2, PPFIBP2, PPP1R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, SOCS2 og DCN, og ét eller flere endogene gener under an-vendelse af kvantitativ PCR; ekspressionsniveauet af biomarkoren P4HB og eventuelt én biomarkor, der er valgt blandt ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, PHKG2, PPFIBP2, PPP1R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, SOCS2 og DCN, normaliseres med det ene eller de flere endogene gener; det normaliserede niveau af biomarkoren P4HB og eventuelt én biomarkor, der er valgt blandt ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, PHKG2, PPFIBP2, PPP1R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, SOCS2 og DCN, sammenlignes med en kontrolvaerdi, hvor forskellig ekspression af biomarkoren P4HB og eventuelt én biomarkor, der er valgt blandt ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, PHKG2, PPFIBP2, PPP1R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, SOCS2 og DCN, indikerer endometriel cáncer eller en foroget sandsynlighed for endometriel cáncer.
22. Fremgangsmáde ifolge krav 21, hvor det ene eller de flere endogene gener er valgt blandt POLR2A, B2M og PFN1.
23. Anvendelse af en nukleinsyre, som er P4HB mRNA, cDNA eller et komplement deraf, til diagnosticering af endometriel cáncer in vitro.
24. Anvendelse af en nukleinsyre, som er en primer for P4HB, til diagnosticering af endometriel cáncer in vitro.
25. Anvendelse af en nukleinsyre, som er en probe for P4HB, til diagnosticering af endometriel cáncer in vitro.
26. Anvendelse af et antistof mod P4HB til diagnosticering af endometriel cáncer in vitro.
27. Anvendelse af et kit, som omfatter en primer for P4HB som defineret i krav 24, til diagnosticering af endometriel cáncer in vitro.
28. Anvendelse af et kit, som omfatter en probe som defineret i krav 25, til diagnosticering af endometriel cáncer in vitro.
29. Anvendelse af et kit, som omfatter et antistof som defineret i krav 26, til diagnosticering af endometriel cáncer in vitro.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09166398 | 2009-07-24 | ||
| PCT/EP2010/004550 WO2011009637A2 (en) | 2009-07-24 | 2010-07-23 | Markers for endometrial cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2456889T3 true DK2456889T3 (da) | 2014-12-01 |
Family
ID=42751506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10736990.2T DK2456889T3 (da) | 2009-07-24 | 2010-07-23 | Markører for endometriel cancer |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9046522B2 (da) |
| EP (2) | EP2848700B1 (da) |
| JP (1) | JP5934093B2 (da) |
| KR (1) | KR101828290B1 (da) |
| CN (2) | CN102549169B (da) |
| AU (1) | AU2010275699B2 (da) |
| BR (1) | BR112012001469B1 (da) |
| CA (1) | CA2767914C (da) |
| DK (1) | DK2456889T3 (da) |
| ES (2) | ES2523683T3 (da) |
| HR (1) | HRP20141062T1 (da) |
| IN (1) | IN2012DN00707A (da) |
| MX (1) | MX2012000921A (da) |
| PL (1) | PL2456889T3 (da) |
| PT (1) | PT2456889E (da) |
| RU (1) | RU2596394C2 (da) |
| WO (1) | WO2011009637A2 (da) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2596394C2 (ru) * | 2009-07-24 | 2016-09-10 | Хеадик Биотек, Аиэ. | Маркеры для рака эндометрия |
| US20130078319A1 (en) * | 2011-09-22 | 2013-03-28 | Memorial Sloan-Kettering Cancer Center | Detection of ovarian cancer |
| EP2787350A1 (en) * | 2013-04-05 | 2014-10-08 | Atlas Antibodies AB | ASRGL1 in endometrial cancer |
| KR102113310B1 (ko) * | 2013-09-03 | 2020-05-20 | 아주대학교 산학협력단 | 암 세포 분리용 조성물, 키트 및 이를 이용한 분리 방법 |
| WO2016025332A1 (en) | 2014-08-12 | 2016-02-18 | President And Fellows Of Harvard College | System and method for monitoring health based on collected bodily fluid |
| KR20170055540A (ko) * | 2014-09-17 | 2017-05-19 | 메르크 파텐트 게엠베하 | 뼈 전이 질환 치료 방법, 그에 따른 약제, 및 뼈 전이 질환 치료의 임상 결과 예측 방법 |
| CN107102141A (zh) * | 2016-02-23 | 2017-08-29 | 中国科学院生物物理研究所 | 分子标记物cd71及在子宫内膜癌诊断、分期及预后中的应用 |
| WO2017180909A1 (en) | 2016-04-13 | 2017-10-19 | Nextgen Jane, Inc. | Sample collection and preservation devices, systems and methods |
| BR112018072498A2 (pt) * | 2016-05-04 | 2019-03-12 | Fundacio Hospital Univ Vall Dhebron Institut De Recerca | marcadores de câncer do endométrio |
| GB201702392D0 (en) * | 2017-02-14 | 2017-03-29 | Univ Edinburgh | Methods for cancer diagnosis using a gene expression signature |
| CN108732350A (zh) * | 2017-04-20 | 2018-11-02 | 中国科学院上海生命科学研究院 | Pla2g6作为指示肝内结节及早期预警肝癌的生物标志物 |
| CN108732351A (zh) * | 2017-04-20 | 2018-11-02 | 中国科学院上海生命科学研究院 | Eps8l2作为指示肝内结节及早期预警肝癌的生物标志物 |
| CN108732349A (zh) * | 2017-04-20 | 2018-11-02 | 中国科学院上海生命科学研究院 | Lta4h作为指示肝内结节及早期预警肝癌的生物标志物 |
| CN109085359A (zh) * | 2017-06-13 | 2018-12-25 | 中国医学科学院肿瘤医院 | 血清蛋白标志物组合在结直肠癌筛查和诊治中的应用 |
| CN117288953A (zh) * | 2017-07-21 | 2023-12-26 | 瓦尔德西布伦大学医院基金会研究所 | 一种子宫内膜癌的预后方法 |
| CN109097462B (zh) * | 2018-09-10 | 2022-01-11 | 青岛市海慈医疗集团 | Ap1m2基因作为诊断青光眼的分子标志物的应用 |
| WO2020130190A1 (ko) * | 2018-12-20 | 2020-06-25 | 경상대학교병원 | 신장암의 발병 위험성 예측 또는 진단을 위한 정보제공방법 |
| CN109797217A (zh) * | 2019-03-27 | 2019-05-24 | 河北医科大学第二医院 | 帕金森生物标志物及其在制备检测产品中的应用 |
| CN109811058B (zh) * | 2019-03-31 | 2021-11-12 | 青岛泱深生物医药有限公司 | 与宫颈疾病发生发展相关的生物标志物及其应用 |
| WO2022226381A1 (en) * | 2021-04-22 | 2022-10-27 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Diagnostic to support clinical trial matching and exploratory biomarker analyses in cancer patients |
| CN114317750A (zh) * | 2021-12-29 | 2022-04-12 | 上海市第十人民医院 | 一种卵巢癌生物标志物及其在制备用于卵巢癌腹水转移疾病的药物或试剂盒中的应用 |
| KR102584898B1 (ko) * | 2022-10-24 | 2023-10-04 | 연세대학교 산학협력단 | 자궁내막암 진단 방법 및 이를 이용한 키트 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| AUPO573697A0 (en) * | 1997-03-20 | 1997-04-10 | Prince Henry's Institute Of Medical Research | Diagnosis of endometrial cancer |
| US7014996B1 (en) * | 1998-10-02 | 2006-03-21 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating gynecologic cancers |
| AUPQ219799A0 (en) | 1999-08-13 | 1999-09-02 | R. Lurie Pty Ltd | Apparatus for obtaining potological samples |
| US6884578B2 (en) * | 2000-03-31 | 2005-04-26 | Affymetrix, Inc. | Genes differentially expressed in secretory versus proliferative endometrium |
| RU2232397C2 (ru) * | 2002-04-03 | 2004-07-10 | НИИ онкологии им. проф. Н.Н. Петрова | Способ ранней диагностики патологических состояний эндометрия |
| US20040063120A1 (en) * | 2002-07-10 | 2004-04-01 | The Regents Of The University Of Michigan | Expression profile of lung cancer |
| US7640114B2 (en) * | 2003-05-21 | 2009-12-29 | The Wistar Institute Of Anatomy & Biology | Method of diagnosis of cancer based on gene expression profiles in cells |
| WO2005034978A2 (en) * | 2003-10-02 | 2005-04-21 | Xantos Biomedicine Ag | MEDICAL USE OF IKKϵ OR OF INHIBITORS THEREOF |
| JP5629894B2 (ja) | 2004-12-07 | 2014-11-26 | 国立大学法人大阪大学 | 甲状腺乳頭癌を診断するための新規のマーカー |
| US7998695B2 (en) * | 2005-02-10 | 2011-08-16 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
| EA200800755A1 (ru) | 2005-09-07 | 2008-10-30 | Лаборатуар Сероно С.А. | Ikk ингибиторы, предназначенные для лечения эндометриоза |
| US20070134687A1 (en) * | 2005-09-12 | 2007-06-14 | Aurelium Biopharma Inc. | Focused microarray and methods of diagnosing cancer |
| SG169395A1 (en) * | 2006-02-09 | 2011-03-30 | Univ South Florida | Detection of cancer by elevated levels of bcl-2 |
| US20070287158A1 (en) * | 2006-06-09 | 2007-12-13 | George Gorodeski | Cell collection and disease screening |
| EP1978106A1 (en) * | 2007-04-07 | 2008-10-08 | Universitätsklinikum Hamburg-Eppendorf | Detection of ESR1 amplification in endometrium cancer and ovary cancer |
| WO2008137591A2 (en) * | 2007-05-02 | 2008-11-13 | Biocept, Inc. | Non-invasive detection of endometrial cancer |
| JP5419195B2 (ja) | 2007-08-03 | 2014-02-19 | 国立大学法人愛媛大学 | 頭頸部癌の腫瘍マーカー |
| WO2009021338A1 (en) * | 2007-08-15 | 2009-02-19 | UNIVERSITé DE SHERBROOKE | Alternative splicing gene variants in cancer detection |
| US8053198B2 (en) * | 2007-09-14 | 2011-11-08 | Meso Scale Technologies, Llc | Diagnostic methods |
| US20110028344A1 (en) * | 2008-04-11 | 2011-02-03 | Expression Pathology, Inc. | Biomarkers for endometrial disease |
| RU2596394C2 (ru) * | 2009-07-24 | 2016-09-10 | Хеадик Биотек, Аиэ. | Маркеры для рака эндометрия |
-
2010
- 2010-07-23 RU RU2012106432/10A patent/RU2596394C2/ru active
- 2010-07-23 EP EP14183077.8A patent/EP2848700B1/en active Active
- 2010-07-23 CN CN201080042678.6A patent/CN102549169B/zh active Active
- 2010-07-23 US US13/386,536 patent/US9046522B2/en active Active
- 2010-07-23 ES ES10736990.2T patent/ES2523683T3/es active Active
- 2010-07-23 DK DK10736990.2T patent/DK2456889T3/da active
- 2010-07-23 ES ES14183077.8T patent/ES2654340T3/es active Active
- 2010-07-23 MX MX2012000921A patent/MX2012000921A/es active IP Right Grant
- 2010-07-23 AU AU2010275699A patent/AU2010275699B2/en active Active
- 2010-07-23 IN IN707DEN2012 patent/IN2012DN00707A/en unknown
- 2010-07-23 CN CN201510425228.XA patent/CN105132529A/zh active Pending
- 2010-07-23 PL PL10736990T patent/PL2456889T3/pl unknown
- 2010-07-23 EP EP10736990.2A patent/EP2456889B1/en active Active
- 2010-07-23 PT PT107369902T patent/PT2456889E/pt unknown
- 2010-07-23 CA CA2767914A patent/CA2767914C/en active Active
- 2010-07-23 WO PCT/EP2010/004550 patent/WO2011009637A2/en active Application Filing
- 2010-07-23 BR BR112012001469-2A patent/BR112012001469B1/pt active IP Right Grant
- 2010-07-23 KR KR1020127004840A patent/KR101828290B1/ko active IP Right Grant
- 2010-07-23 JP JP2012520964A patent/JP5934093B2/ja active Active
-
2014
- 2014-11-03 HR HRP20141062AT patent/HRP20141062T1/hr unknown
-
2015
- 2015-06-01 US US14/727,549 patent/US20150337392A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2012106432A (ru) | 2013-08-27 |
| EP2456889A2 (en) | 2012-05-30 |
| IN2012DN00707A (da) | 2015-06-19 |
| CA2767914C (en) | 2020-02-25 |
| CN102549169B (zh) | 2016-02-24 |
| RU2596394C2 (ru) | 2016-09-10 |
| PT2456889E (pt) | 2014-11-21 |
| ES2654340T3 (es) | 2018-02-13 |
| CN102549169A (zh) | 2012-07-04 |
| BR112012001469B1 (pt) | 2021-08-10 |
| US20120122726A1 (en) | 2012-05-17 |
| KR101828290B1 (ko) | 2018-02-12 |
| PL2456889T3 (pl) | 2015-02-27 |
| EP2848700B1 (en) | 2017-10-04 |
| MX2012000921A (es) | 2012-06-12 |
| WO2011009637A2 (en) | 2011-01-27 |
| HRP20141062T1 (hr) | 2015-01-02 |
| ES2523683T3 (es) | 2014-11-28 |
| US9046522B2 (en) | 2015-06-02 |
| WO2011009637A3 (en) | 2011-04-14 |
| JP2013500001A (ja) | 2013-01-07 |
| EP2456889B1 (en) | 2014-09-03 |
| BR112012001469A2 (pt) | 2020-08-11 |
| JP5934093B2 (ja) | 2016-06-15 |
| US20150337392A1 (en) | 2015-11-26 |
| CN105132529A (zh) | 2015-12-09 |
| AU2010275699A1 (en) | 2012-02-02 |
| CA2767914A1 (en) | 2011-01-27 |
| KR20120047334A (ko) | 2012-05-11 |
| AU2010275699B2 (en) | 2016-06-16 |
| EP2848700A1 (en) | 2015-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2456889T3 (da) | Markører for endometriel cancer | |
| US20060046257A1 (en) | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer | |
| BRPI0708534A2 (pt) | ensaio molecular para prognosticar a recorrência de cáncer do cólon dukes b | |
| US9624547B2 (en) | Salivary transcriptomic and proteomic biomarkers for breast cancer detection | |
| WO2005024055A1 (en) | Methods of diagnosis and prognosis of ovarian cancer ii | |
| US20140357518A1 (en) | Methods and Compositions for the Treatment and Diagnosis of Thyroid Cancer | |
| EP1565579B1 (en) | Methods for identifying risk of breast cancer | |
| US20110151443A1 (en) | Marker for gastric cancer | |
| EP3714070B1 (en) | A novel cip2a variant and uses thereof | |
| US6617104B2 (en) | Predisposition to breast cancer by mutations at the ataxia-telangiectasia genetic locus | |
| KR101683961B1 (ko) | 방광암 재발 진단 마커 | |
| US7355025B2 (en) | Marker molecules associated with lung tumors | |
| JP5072901B2 (ja) | 薬剤耐性マーカーおよびその利用 | |
| KR20170124683A (ko) | 담도암 진단용 신규 바이오마커로서의 융합 유전자 및 융합 단백질 | |
| KR101093508B1 (ko) | 대장암 진단용 조성물 및 그 용도 | |
| CA2569100A1 (en) | Methods for identifying risk of breast cancer and treatment thereof | |
| KR20210040921A (ko) | 신장암 환자의 치료 전략 결정 및 예후 진단용 재발 특이적 마커 | |
| KR20190083801A (ko) | 데스모글레인 3의 유전적 변이 및 이의 용도 | |
| JP2007503826A (ja) | 乳癌のリスクの診断 | |
| KR20110036558A (ko) | 대장암 진단용 조성물 및 그 용도 | |
| KR20110036557A (ko) | 대장암 진단용 조성물 및 그 용도 | |
| KR20110036556A (ko) | 대장암 진단용 조성물 및 그 용도 |